Breast Carcinoma Case Study

The clinicopathologic records for each patient were published previously [17] (Table 1). The average age of the randomly selected group of 100 breast carcinoma cases with stage I (24%), stage II (39%), stage III (33%), and stage IV (2%) and two patients undetermined disease was about 51.5 years. Fifty-eight percent of the patients were premenopausal cases, with an average age of 37.5 years. The average age of postmenopausal patients was 61.2 years.
Numerous publications have reported aberrant miRNA expression in cancer. Figure 1 shows the relative quantification of miRNAs hs-miR-196a2, hs-miR-499 and hs-miR-146a in the blood of 89 healthy individuals and 92 patients with breast cancer (RNA quality or quantity was insufficient for expression study in 8 out of the 100 samples, which will be the subject of future investigation; thus the final analyses included 92 cases out of the 100). To determine the differences in the relative expression profiles, we performed univariate analyses using the Mann Whitney-U test. Quantitative reverse transcriptase-polymerase chain reaction assays confirmed this finding. As shown in Figure 2, the median values of hs-miR-196a2 for the pre- and post-menopausal …show more content…
We found that among the 92 breast cancer patients, 25 were of the rs11614913 TT genotype (hs-miR-196a2), 44 of the CT genotype, and 23 of the CC genotype. The ΔCt value for hs-miR-499 of the rs3746444 TT genotype was 5.12±0.36; the CT genotype was 4.66±1.03; and the CC genotype was 4.16±0.3, whereas ΔCt values for mature hs-mir-196a according to different rs11614913 genotypes were 5.83±0.77 (24), 4.53±0.75 (42), and 3.89±0.28 (26), respectively. However, the ΔCt value for the hs-miR-146a miRNA (rs2910164) TT genotype was 1.74±0.07 (29); the CT genotype was 1.72±0.06 (35), and 0.59±0.28 (26) for the CC genotype (P =